Powered by

Nicox's Partner Secures Additional Approvals of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina

Jan 16, 2020 - Thomson Reuters ONE

Press Release Nicox's Partner Secures Additional Approvals of VYZULTA(R) (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina January 16, 2020 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Bausch + Lomb, has received approval for VYZULTA(R) (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina. With these approvals, VYZULTA i...